171 related articles for article (PubMed ID: 34660511)
1. R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry.
Su CY; Guo YN; Chai KC; Kong WW
Front Public Health; 2021; 9():708832. PubMed ID: 34660511
[TBL] [Abstract][Full Text] [Related]
2. Institutional investors and cost of capital: The moderating effect of ownership structure.
Huo X; Lin H; Meng Y; Woods P
PLoS One; 2021; 16(4):e0249963. PubMed ID: 33831116
[TBL] [Abstract][Full Text] [Related]
3. Public funding and private investment for R&D: a survey in China's pharmaceutical industry.
Qiu L; Chen ZY; Lu DY; Hu H; Wang YT
Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505
[TBL] [Abstract][Full Text] [Related]
4. Sovereign wealth fund investments and financial performance of target firms: The disciplinary role of debt in political agenda theory.
Rasheed S; Adeneye Y; Kosnin R
Heliyon; 2023 May; 9(5):e15519. PubMed ID: 37144204
[TBL] [Abstract][Full Text] [Related]
5. Reducing carbon emissions at the expense of firm physical capital investments and growing financialization? Impacts of carbon trading policy from a regression discontinuity design.
Liu H; Pan H
J Environ Manage; 2024 Apr; 356():120577. PubMed ID: 38484596
[TBL] [Abstract][Full Text] [Related]
6. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
Hu Y; Chen S; Qiu F; Chen P; Chen S
Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
[TBL] [Abstract][Full Text] [Related]
7. China's Outward Direct Investment in the United States: From the perspective of agglomeration economies.
Liang X; Wang J; Lin B; Cao X; Si Y
PLoS One; 2022; 17(6):e0269602. PubMed ID: 35687568
[TBL] [Abstract][Full Text] [Related]
8. Will China's R&D investment improve green innovation performance? An empirical study.
Fan J; Teo T
Environ Sci Pollut Res Int; 2022 Jun; 29(26):39331-39344. PubMed ID: 35099703
[TBL] [Abstract][Full Text] [Related]
9. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
Han E; Kim TH; Jeung MJ; Lee EK
Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
[TBL] [Abstract][Full Text] [Related]
10. Investment analysis of the private firm under different financial arrangements in infrastructure projects.
Ding Q; Huang S; Fu G; Wang B
PLoS One; 2024; 19(2):e0287418. PubMed ID: 38363762
[TBL] [Abstract][Full Text] [Related]
11. Governance, financial development and China's outward foreign direct investment.
Gao C; Wen Y; Yang D
PLoS One; 2022; 17(6):e0270581. PubMed ID: 35771853
[TBL] [Abstract][Full Text] [Related]
12. The nexus between capital structure, firm-specific factors, macroeconomic factors and financial performance in the textile sector of Pakistan.
Ullah A; Pinglu C; Ullah S; Zaman M; Hashmi SH
Heliyon; 2020 Aug; 6(8):e04741. PubMed ID: 32895635
[TBL] [Abstract][Full Text] [Related]
13. Green credit, environmental protection investment and debt financing for heavily polluting enterprises.
Ji L; Jia P; Yan J
PLoS One; 2021; 16(12):e0261311. PubMed ID: 34910790
[TBL] [Abstract][Full Text] [Related]
14. China's Insurance Regulatory Reform, Corporate Governance Behavior and Insurers' Governance Effectiveness.
Li H; Zhang H; Tsai SB; Qiu A
Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 29039781
[TBL] [Abstract][Full Text] [Related]
15. The causal effect on firm performance of China's financing-pollution emission reduction policy: Firm-level evidence.
Zhang D; Vigne SA
J Environ Manage; 2021 Feb; 279():111609. PubMed ID: 33218832
[TBL] [Abstract][Full Text] [Related]
16. Can capital markets identify heterogeneous environmental investment strategies of firms? Evidence from China.
Cheng H; Feng Y
Environ Sci Pollut Res Int; 2023 Apr; 30(20):58253-58275. PubMed ID: 36977868
[TBL] [Abstract][Full Text] [Related]
17. Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry.
Wu D; Wang S; Chang S; Lian G; Chen Y
PLoS One; 2022; 17(6):e0270271. PubMed ID: 35731793
[TBL] [Abstract][Full Text] [Related]
18. Research on U-shaped relationship between short-term debt for long-term use and supply chain enterprise default risk: Evidence from Chinese listed firms.
Shen H; Chen J
PLoS One; 2023; 18(10):e0293284. PubMed ID: 37871103
[TBL] [Abstract][Full Text] [Related]
19. The diminishing marginal contribution of R&D investment on green technological progress: a case study of China's manufacturing industry.
Zhang X; Li R; Zhang J
Environ Sci Pollut Res Int; 2023 Feb; 30(6):14190-14199. PubMed ID: 36151434
[TBL] [Abstract][Full Text] [Related]
20. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
Lee M
Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
